The megamerger passes a federal judge’s scrutiny.
A federal judge reviewing a Justice Department decision to allow CVS Health to merge with the health insurer Aetna said on September 4 that the agreement was legal under antitrust law, Reuters reports.
U.S. District Judge Richard J. Leon had been reviewing a government plan, announced in October, to allow the merger on the condition that Aetna sell its Medicare prescription drug plan business to WellCare Health Plans. Both deals have already been closed.
Leon had initially balked at approving the merger conditions and insisted on hearing from critics of the deal, but finally decided to grant the motion to approve the consent agreement. But he took aim at the common practice of companies’ closing multibillion-dollar deals while the court review, required by the Tunney Act, was still in progress.
Related: Opinion: Top Two Ways The CVS-Aetna Merger Will Shake Up Healthcare
In his ruling, the judge said that the court must determine what is in the public’s interest. “That determination in this particular case, however, is no small matter,” he wrote. “Industry players, consumer groups, and state regulatory bodies have all raised concerns about CVS’s acquisition of Aetna. The merger combines two healthcare giants. Its effects, for better or worse, will be felt by millions of consumers.
“If the Tunney Act is to mean anything,” Leon continued, “it surely must mean that no court should rubber-stamp a consent decree approving the merger of ‘one of the largest companies in the United States’ and ‘the nation’s third largest health insurance company,’ simply because the government requests it.”
In December, the judge said he was “less convinced” than the government that the asset sale to WellCare would resolve antitrust concerns. Since then, Centene had agreed to acquire WellCare for $15.27 billion.
According to a statement by CVS spokesman T.J. Crawford, “CVS Health and Aetna have been one company since November 2018, and (the) action by the District Court makes that 100% clear. We remain focused on transforming the consumer healthcare experience in America.”
Related: Tufts Health Plan, Harvard Pilgrim Health Care Intend to Merge
Critics of the CVS-Aetna deal included the American Medical Association (AMA) and the AIDS Healthcare Foundation.
Patrice A. Harris, MD, MA, president of the AMA, said in a statement, “Despite an unprecedented review that dragged many details of this merger into the light, (the) decision ultimately fails patients, will likely raise prices, lower quality, reduce choice, and stifle innovation. The American people and our health system will not be served well by allowing a merger that combines health insurance giant Aetna Inc. with CVS Health Corporation––the nation’s largest retail pharmacy chain, specialty pharmacy, pharmacy benefit management (PBM) and Medicare Part D Stand-Alone Prescription Drug Plan (PDP) insurer.
“For patients and employers struggling with recurrent increases to health insurance premiums, out-of-pocket costs, and prescription drug prices, it's hard to find any upside to a merger that leaves them with fewer choices. Nothing in the deal guarantees reductions on insurance premiums or prescription drug costs. As for promised efficiency savings, that money will likely go straight to CVS’s bottom line. CVS made no commitment to pass much-hyped savings onto consumers through lower premiums or drug costs.
“Although this outcome is not what we fought for, the AMA is optimistic that this case and the thorough examination of its underlying facts are a sign of things to come. When the public interest is harmed by healthcare mergers, courts charged with scrutinizing DOJ merger settlements must not be a rubber stamp.”
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
Upended: Can PBM Transparency Succeed?
March 6th 2024Simmering tensions in the pharmacy benefit management (PBM) industry have turned into fault lines. The PBMs challenging the "big three" have formed a trade association. Purchaser coalitions want change. The head of the industry's trade group says inherent marketplace friction has spilled over into political friction.
Read More
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
The deliberate disconnection of Change Healthcare to ring fence a cyberattack entered its seventh day today. Prescribers are finding ways to get pharmacy claims processed, and UnitedHealth Group says disruption to the dispensing of prescriptions has been minimal. But independent pharmacies want more information and protection from financial consequences from pharmacy benefit managers.
Read More